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Consequenoes for the Practice of Oral Anticoagulation
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Abstract. A short review on the discovery of the relation between vitamin K and the syn-
thesis of clotting factors and on the development of anticoagulant herapy is given. The pro-
coagulant actiyity induced by vitamin K resides in the postribosomal modification of N-
terminal glutamic acids in y-COOH glutamic acids. The mode of action of oral anticoagulants
is explained. The concentration-effect relations and the choice ofan oral anticoagulant is dis-
cussed.
History
In the 1920s and 1930s, two different lines
of research led to the discovery of vitamin K
and its antagonists. Dam ?nd co-workers [1,
2l as well as Almquist and Stol<stead [3] ob-
served an acquired bleeding syndrome in
chicken which were fed a fat-free diet. Dam
eI al. [2] postulated the existence ofa nutri-
tion factor that was essential for normal he-
mostasis, and called it vitamin K. By clinical
observations on patients suffering from he-
patic cirrhosis and obstruction ofthe biliary
ducts and also by animal experiments, it soon
became clear that intimate links exist be-
tween liver function, gall secretion, vitamin
K and the synthesis ofclotting factors.
Only 10 years after the frrst announce-
ment of the possible existence of vitamin K,
its chemical structure and its synthesis were
reported [4, 5]. ln 1943, Dam and Doisy
obtained the Nobel Prize for this work.
Another line of research started, when, in
1920, Schofield, 16l a veterinarian from the
United States, described a hemorrhagic dia-
thesis in cattle that was caused by the inges-
tion of spoiled, sweet clover. The cause of the
bleeding could be identified as an extremely
low'prothrombin' level [7], which, interpret-
ing the data of that time in terms of the
knowledge of today means low levels of the
vitamin K-dependent clotting factors. In
1940, Link [8] could define dihydroxycou-
marin as the toxic substance responsible for
the low level of clotting factors. He could also
show that these substances acted as vitamin
K antagonists. Later it was found that two
diflerent basic structures could serve as vita-
min K antagonists: 4-OH coumarins and 1,3-
indanedione t8l. All oral anticoagulants
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presently in use are derivatives ofthese sub-
stances.
Recently the so-called'superwarfarins'
have been developed that are characterized
by an extremely slow elimination from the
body. These substances are used as rodenti-
cides rather than as oral anticoaeulants for
humans [9].
Clinical experience in the 1930s showed
that antivitamin K drugs could be useful
therapeutics in thromboembolic events [for
review, see l0l. Thus, after 1941, they found
a place in the therapeutic arsenal, especially
for treating venous thrombosis. Their use in
the treatment of arterial thrombosis re-
mained a matter of debate during many years
and, as a matter of fact, hardly can be consid-
ered 1o be settled at this moment, were it not
for the recent work of Loeliger et al. I l]. In
fact the continuing debate on this matter may
be caused by the fact that for arterial throm-
bosis the gap between elficient therapeutics
and an unacceptable risk ofbleeding, i.e. the
therapeutic range, is extremely narrow,
whereas in venous thrombosis it is somewhat
wider (see elsewhere in this volume). It has
been Loeliger's merit to devote his efforts to
(a) defining the width of the therapeutic
range, and (b) finding ways to maintain a
large proportion of the patients under treat-
ment within this range.
Procoagulant Activity of Yitamin K
The first problem that Loeliger asked me
(H.C.H.) to tackle when I became the re-
search biochemist in his department in 1962
was a practical problem in the control oforal
anticoagulation. A patient with hepatic cir-
rhosis and a level of the vitamin K-depen-
dent coagulation factors of about 300/o will
show a Thrombotest percentage of 300/o as
well, which is to be expected because factors
II, VII and X determine the Thrombotest
value. A patient under anticoagulant treat-
ment however, who also has 300/o f each of
the factors II, VII and X, will show only
about l5 o/o in the Thrombotest.
An application of enzyme kinetic tech-
niques to the analysis ofclotting tests enabled
us to show that in the plasma of these pa-
tients a protein occurs that inhibits the
Thrombotest but not, or hardly, the deter-
mination of clotting factors. This inhibitor
could be shown to be a prothrombin-like pro-
tein. We therefore drew the conclusion that
vitamin K acts as a postribosomal modifier
of a precursor protein [12]. The inhibitor
itself we called PIVKA - protein induced by
vitamin K absence. It is a pleasure to see that
this name by now is widely accepted in the
coagulation literature, be it more often than
not without a citation.
One year laler, Josso et al. [pers. commun.]
showed that plasma from anticoagulated pa-
tients indeed contained two populations of
molecules that both reacted with antipro-
thrombin antibodies, but that differed in elec-
trophoretic mobility in the presence of Ca**
ions. They did not publish their results until
1968 [4], at the same time as Ganroth and
Nilehn [3]. Later we could demonstrate the
existence of similar analogues of the other
vitamin K-dependent factors, both in man
and in the cow [ 5]. They did not occur in the
chicken or the rat though. Also we could show
that the inhibition of coagulation by PIVKA
takes place at the level of factor X, so that
PIVKA-X probably is the inhibitory protein.
The inhibition by PIVKA is specific for hu-
man plasma, it is not observed in the cow.
It is important for the practice of the con-
trol oforal anticoagulation that the inhibition
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by PIVKA is dependent upon the type of
thromboplastin used. It is evidently a phos-
pholipid-dependent phenomenon. Nonphys-
iological prothrombin activators such as
Echis carinalrs venom, trypsin or staphylo-
coagulase activate PIVKA like they activate
normal prothrombin [6]. These activators
can therefore not be used for the control of
anticoagulant reatment. The fact that E. car-
inatusvenom contains a factor X activator as
well as a factor Il-activating enzyme may
sometimes cause confusion in this matter
u7l.
A combination of our kinetic work and
the findings of Josso et al. [4] and Ganroth
and Nilehn [3] led to the conclusion that the
procoagulant activity induced by vitamin K
resides in a postribosomal modification of
the vitamin K-dependent coagulation factors
that also involved their Ca** binding prop-
erties. It was Stenflo [8, l9], who at the
Second Boerhaave Conference in leyden in
1974 revealed what was the nature of the
chemical change involved. As he stated: nor-
mal prothrombin is an abnormal protein in
that the glutamic acid residues at its N-termi-
nal end have been modified to 1-COOH glu-
tamic acids. Abnormal prothrombin, on the
contrary, is a normal protein that contains
only normal glutamic acids.
Vitamin K-Dependent Carboxylation and
the Yitamin K Cycle
In the hepatocyte, vitamin K functions in
a metabolic cycle coupled to the carboxyla-
tion of the glutamyl residues at the N-termi-
nal end of the vitamin K-dependent clotting
factors. In many other organs, including kid-
ney, bone, testis and arterial (but not ve-
nous!) wall, vitamin K-dependent carboxyla-
tion takes place. The nature and function of
the proteins thus produced is often unknown
and we will restrict ourselves to a discussion
ofclotting factor synthesis in the liver.
Two questions apparently arise here. First
why are some proteins carboxylated and only
in specific residues? And second, what is the
molecular mechanism of this carboxylation?
The frrst question can as yet not be answered.
The carboxylase is situated at the inside of
the rough endoplasmatic reticulum. There-
fore, only the proteins that are to be secreted
by the cell can be carboxylated, but the spec-
ificity of this conversion within this group of
proteins is as yet an unsolved problem. The
second question can be considered to be
largely solved however. The frnding by De
Metz et al. [20] of vitamin K hydroperoxide
as an intermediate in the vitamin K cycle
enabled to arrive at a plausible molecular
mechanism of carboxylation. Some details
remain to be solved, but the broad lines are
as depicted in figure l. In the vitamin K
cycle, concurrent with carboxylation, a vita-
min K epoxide is formed that has to be
reduced in two steps so as to form vitamin K
hydroperoxide again. In vitro, working with
the purified carboxylase, many different
agents may serve to bring about these reduc-
tions. What the specific reducing agent is in
vivo remains as yet unknown. This question
may not be unimportant though, because it
may be relevant for the design of oral antico-
agulant treatment, as we will presently see.
Mode of Action of Oral Anticoagulants
Oral anticoagulants do not interfere with
vitamin K-dependent carboxylation per se,
but they block the vitamin K cycle by block-
ing its reducing reactions l2l, 221. y-Hy-
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Fig. l. The vitamin K cycle. The
arrow at the lower left corner indi-
cates the site of entry of exogenous
vitamin K.
therapy. It has been observed in rats lVer-
meer, pers. commun.l that the simultaneous
administration of vitamin K and an antico-
agulant in relatively high doses results in a
more stable anticoagulation than the admin-
istration ofthe anticoagulant alone. This may
be a pharmacokinetic effect but it may also
result from complete inhibition of one or
both specific reductases and the bypassing of
the aspecific reductases by NAD(P)H-depen-
dent reductases in the cytosol.
Concentration-Effect Relations
The vitamin K-dependent clotting factors
(factors II, VII, IX and X, proteins C and S),
like all other plasma proteins, obtain a
steady-state concentration in the plasma be-
cause they are synthesized at a given rate and
droxycoumarins and indanediones share this
type of action. The quinone reductase is more
sensitive to the inhibition than the epoxide
reductase is, at least in vitro 123,241. It does
appear possible however that there is not one
unique reductase but one or more specifrc
ones located in the endoplasmatic reticulum
that are sensitive to oral anticoagulants and
besides that an aspecific NAD(P)H-depen-
dent one in the cytosol that only functions at
high concentrations of vitamin K.
It has been found that vitamin K, admin-
istered orally to anticoagulated patients, oc-
curs in the plasma in its epoxy form. This
suggests preferential inhibition of the first
reduction step, but it may also be due to the
fact that an excess of the quinone can be
transformed into the hydroquinone by an
aspecifrc uninhibited pathway. This would
not be without interest for anticoagulant
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II
VII
x
X
Table I. Data on the synthesis of vitamin K-
dependent coagulation factors
MW
crease to the same level in steady oral anti-
coagulation 1251, it can therefore be con-
cluded that prothrombin carboxylase is in-
hibited to the same extent as factor VII car-
boxylase. It cannot be excluded that the same
enzyme serves to carboxylate all coagulation
factors.
If it were theoretically possible to inhibit
the synthesis in a sudden way to a stable 20olo
level, then the factors would approach their
new level in a monoexponential way, again
determined by their half-life times. That is
why the halflife times of the vitamin K-
dependent factors are important for the un-
derstanding of the management of anticoagu-
lation. In general, it is considered to last 4-5
times the half-life time before a new equilib-
rium is approached. Factor VII will therefore
be at its steady inhibited level in about I day,
but for factor II this will last more then l0
days. The inhibition of clotting factors syn-
thesis obtained by the daily intake ofan oral
anticoagulant needs by no means be stable
however. It depends upon the antagonism in
the liver cell ofthe anticoagulant and vitamin
K. The fluctuations in the concentration of
the drug may be important if an anticoagu-
lant is used that is eliminated quickly, such as
acenocoumarol. The halflife time of this
drug on itself is about l0 h, so that the level
of the drug at the site of action will vary from
an optimum shortly after oral intake and a
minimum just before intake that is only l5-
25o/o of the optimum. Because the coagula-
tion factors have their own half-life time, the
plasma levels will follow these fluctuations
with an appreciable backlash (frg.2, 3). Be-
cause of its long half-life time, prothrombin
levels will hardly vary, even when a short-
lived coumarin derivative is used. Factor VII
and protein C however will show important
variations. This . has two important conse-
66,000
45,500
70,000
55,000
60
6
t 4
40
1,500 1.6 77.8
10  l l . 6  7 .25
70 4.95 r5.7
180 1.73 15.0
MW = molecular weight; tYz = half-life time (h);
C = plasma concentration (nmol); K = breakdown
constant; SR = synthesis rate, nmol/h for a man of
about 70 kg.
broken down with a velocity that is propor-
tional to their concentration. When the syn-
thesis is blocked the clotting factors disap-
pear from the plasma in a process that, if we
disregard the exchange with extravascular
space for the moment, may be described as a
monoexponential decay.
The velocity ofthe decay is determined by
the half-life of the clotting factors - factor VII
and protein C disappearing the fastest, pro-
thrombin slowest (table I). If the synthesis is
not completely blocked but for example in-
hibited to 20o/o of its original value, then a
new equilibrium will be found when again
the breakdown velocity is equal to the new
velocity ofsynthesis. Because the breakdown
velocity is directly proportional to the
plasma level of the clotting factor - as can be
concluded from the monoexponential decay
- the clotting factor level in the new steady-
state equilibrium will be 20o/o of the normal
level. In general, the level of clotting factors
in the equilibrium situation reflects the de-
gree of inhibition of the synthesis system.
From the fact that in good approximation all
vitamin K-dependent clotting factors de-
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Fig.2. The e{Iect ofa short-lived anticoagulant on
the plasma levels of factors II and VIL Computer
simulation of the effects of a drug with a half-life time
of 10 h. Q = plasma level ofthe drug; syn/syn'= rela-
tive rate of synthesis in the liver; II = plasma level of
factor II; VII = plasma level of factor VII [26].
quences. In the first place factor VII may,
during appreciable parts ofthe day, be either
above the level that ensures adequate anti-
coagulation or below the level that guarantees
safe anticoagulation. Because the importance
for the state ofanticoagulation ofthe individ-
ual clotting factors remains unknown, we do
not now what upper and lower levels of factor
VII are compatible with adequate thrombo-
sis prevention. It would therefore be prudent
to maintain this factor within the levels that
are known to be safe on the bases ofoverall
tests (say l0-200/o). This cannot be achieved
with a short-lived drug like acenocoumarol.
The other risk of using a short-lived drug
is the fact that the fluctuating levels offactor
VII will cause fluctuations in the outcome of
the test used to monitor the therapy. When
the time lap between drug intake and blood
sampling varies this will cause the daily vari-
ations that are to be expected ifa short-lived
Fig.3. The effect of a longJived anticoagulant in
the plasma levels of factors II and VII. As frgure 2 but
for a drug with a half-life time of 70 h [26].
drug us used, to appear as changes in the
level of steady-state anticoagulation. It thus
is easily understood that even a very good
thrombosis service will maintain only about
75olo f its patients within the proper bound-
aries of anticoagulation if acenocomarol is
used. With a long-lived anticoagulant, such
as phenprocoumon (half-life time - 5 days),
85-90o/o f the patients are within the limits.
The effect of this on the success of therapy
has not been systematically studied until
now but for one case fLubsel?, pers. com-
mun.l. In a study of the Interuniversity Car-
diological Institute of The Netherlands on
the influence ofanticoagulant herapy on the
patency of coronary bypasses, it could be
shown that the odds ratio, i.e. the ratio of the
risk of occlusion in the presence of therapy
over that in the absence oftherapy, is 0.6 for
acenocoumarol treatment and 0.3 for phen-
procoumon treatment. These diflerences are
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significant. It may be noted, moreover, that
the odds ratio for antiplatelet treatment is a
nonsignificant 0.8.
Choice of an Oral Anticoagulant
From the above it will be clear that on the
basis of our understanding of the mechanism
ofaction oforal anticoagulant, a long-acting
anticoagulant is by far to be preferred. Yet
the short-acting acenocoumarol is by far the
most used. In several European countries
phenprocoumon cannot even be obtained.
This is largely due to a misunderstanding of
the nature of the 'quick-acting', short-lived
anticoagulants.
It is largely thought that acencoumarol
will produce the desired level of anticoagula-
tion more quickly than phenprocoumon. The
uptake of both drugs and their mode of ac-
tion are completely comparable however.
The onset ofan acceptable level ofanticoagu-
lation is determined by a physiological con-
stant: the disappearance rate of the clotting
factors, and by that constant only.
The other admitted advantage of a short-
lived anticoagulant is that cessation of ther-
apy suffices to obtain normal coagulability.
This is indeed true. If, however, phenprocou-
mon therapy is stopped by daily administra-
tion of 5-10 mg vitamin K for a week then
there is no diflerence whatsoever in the ve-
locity of approach to normal coagulability;
again because it is the physiological synthesis
rate of the clotting factors rather then the
pharmacokinetics of the drug that determines
the course ofevents.
A consideration of the pros and cons of
short- and long-lived anticoagulants must
therefore inevitably decide in favour of the
longJived ones [26].
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